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Cardiac and kidney diseases are common, increasingly encountered, and often coexist. Recently, the Acute Dialysis Quality
Initiative (ADQI) Working Group convened a consensus conference to develop a classiﬁcation scheme for the CRS and for
ﬁve discrete subtypes. These CRS subtypes likely share pathophysiologic mechanisms, however, also have distinguishing clinical
features, in terms of precipitating events, risk identiﬁcation, natural history, and outcomes. Knowledge of the epidemiology
of heart-kidney interaction stratiﬁed by the proposed CRS subtypes is increasingly important for understanding the overall
burden of disease for each CRS subtype, along with associated morbidity, mortality, and health resource utilization. Likewise,
an understanding of the epidemiology of CRS is necessary for characterizing whether there exists important knowledge gaps and
to aid in the design of clinical studies. This paper will provide a summary of the epidemiology of the cardiorenal syndrome and its
subtypes.
1.Introduction
On a global scale, evolving changes in demographics have
lead to an aging population along with increasing rates
of obesity, diabetes mellitus (DM), and hypertension.
These emerging pandemics have also focused considerable
attention on the public health importance and the broad
implications of increasing rates of heart disease, kidney
disease, and the concomitant occurrence of both heart and
kidney disease.
Anestimated1in3adultsintheUnitedStatesofAmerica
(USA) (or greater than 80 million persons) has a diagnosis of
cardiovascular disease (CVD) (i.e., hypertension, coronary
heartdisease(CHD),heartfailure(HF),stroke,orcongenital
heart disease) [1]. In the USA, the prevalence of any stage
CKD has been recently estimated at 13% representing
close to 30 million adults [2]. CKD has also emerged as an
important and potentially modiﬁable predictor of CVD,
including CHD, left ventricular hypertrophy, and HF [3].
Increasingly, there is recognition of the considerable clinical
overlap and complex pathophysiology between CKD and
CVD [4]. Cardiovascular disease may account for greater
than 50% of all deaths in patients with CKD, occurring at
rates 10- to 20-fold higher than an age-matched non-CKD
population [5, 6]. This epidemic of CKD has potential
far-reaching economic implications, as patients with CKD
are more likely to be hospitalized, consume greater health
resources, and have higher costs of care, both of which are
increased further after progression to ESKD [7].
A description of the epidemiology of heart-kidney
interactions is critical to understanding not only to overall
burdenofdiseaseforeachoftheproposedCRSsubtypes,but
also their natural history, risk factors, associated morbidity
andmortality,andpotentialhealthresourceimplications[8].
Likewise, an appreciation for the existing literature on the
epidemiology and outcomes of CRS is necessary for recog-
nizing whether there are important knowledge gaps and for
the design of future observational studies and clinical trials.
This paper will summarize the epidemiology and clinical
outcomes associated with the CRS stratiﬁed by its subtypes.2 International Journal of Nephrology
2. Type 1 CardiorenalSyndrome:
Acute Cardiorenal Syndrome
The Acute Cardiorenal Syndrome (Type 1 CRS) is charac-
terized by acute worsening of heart function leading to acute
kidneyinjury(AKI)and/ordysfunction.Acutecardiacevents
that may contribute to AKI include acute decompensated
heart failure (ADHF), acute coronary syndrome (ACS), car-
diogenic shock, and cardiac surgery-associated low cardiac
output syndrome.
Mostly commonly, observational studies have evaluated
the development of AKI in association with ADHF and ACS
(Tables 1 and 2). Many of these studies are limited in scope
due to being performed retrospectively or being secondary
and/or post hoc analyses from large databases [9–13]
or secondary or analyses of clinical trials of drug therapy
[8, 14, 15].
Most of these studies also use the term “worsening renal
failure(WRF)”todescribetheacuteand/orsubacutechanges
in kidney function that occurs following ADHF or ACS.
For example, WRF has been deﬁned as increases in serum
creatinine (SCr) ≥26.5µmol/L (0.3mg/dL) [10, 13–16, 25–
27], ≥44.2µmol/L (0.5mg/dL) [9, 10, 12, 13, 27, 28], ≥25%
relative to SCr at the time of hospital admission, ≥50% at
the time of hospital admission, and as the combined increase
of ≥26.5µmol/L (0.3mg/dL) and ≥25% increase [17].
Stud-ies have also evaluated WRF as even smaller increments
of rise in SCr (≥8.8µmol/L (0.1mg/dL)) [10, 12, 27]o ra s
rate of decline in estimated GFR (eGFR) [29]. Aronson et
al. evaluated WRF deﬁned by a 50% increase in blood urea
nitrogen above admission values [30]. Incidence estimates of
WRF associated with ADHF and ACS have ranged between
24%–45% and 9%–19%, respectively. A small single center
study found that AKI occurred in 48% of pediatric patients
admitted for ADHF [31]. This wide range in incidence is
attributed to diﬀerences in the deﬁnitions used for WRF, in
the observed time-at-risk after hospitalization, and due to
heterogeneity of the study populations.
Studies have used variable durations of observed time-
at-risk for ascertainment of WRF. For example, in a cohort
admitted with ADHF, Gottlieb et al. showed that 47% had
WRF within three days of hospitalization [10]. Cowie et al.
found that 50% occurred within four days [25]. Whereas,
two observational studies found that 70%–90% of all WRF
hadoccurredwithintheﬁrstweekofhospitalization[11,25].
Still, other studies have observed for WRF for 2 weeks [14]
and up to 6 months [32]. These variations in ascertainment
for WRF have the potential to introduce bias and misclassiﬁ-
cation. The most common deﬁnition for WRF has been any
time within hospital admission [10, 11]. However, data have
shownthatthevastmajorityofWRFoccursearlyafterhospi-
tal admission. Moreover, it is important to recognize that the
pathophysiology of WRF/AKI likely varies at diﬀerent time
points. For example, WRF at presentation may be due to
congestion and low cardiac output; however, investigations
(i.e., cardiac catheterization and contrast media exposure)
or interventions (i.e., furosemide, angiotensin converting
enzyme [ACE] inhibitors) may impact kidney function and
contribute, in part, to late WRF. These potential inﬂuences
have not been well described in terms of time of onset of
WRF.
The pathophysiologic mechanisms leading to WRF in
ADHF are numerous and complex, but likely include
alterations to cardiac output and systemic hemodynamics
compromising kidney perfusion [33, 34] and pathologic
compensatory neurohormonal activation [35]. An impor-
tant risk factor also includes baseline kidney function and
presenceofCKD[19,36].Aronsonetal.recentlyshowedthat
persistent WRF after admission for ADHF was more likely in
those with worse baseline kidney function [18]. Few studies
have investigated the time course of WRF and whether there
are observed diﬀerences in clinical outcome associated with
transient WRF or persistent stepwise declines in kidney
function after hospitalization for ADHF. Recently, Aronson
et al. investigated this issue in a cohort of 467 patients
admitted with ADHF [18]. WRF was deﬁned as an absolute
increase in SCr ≥ 44.2µmol/L, whereas transient was deﬁned
as return to baseline within 30 days and persistent WRF
as a sustained increase in SCr ≥ 44.2µmol/L beyond 30
days. Of those developing WRF (33.9%), transient and
persistent WRF occurred in 7.9% and 14.3%, respectively.
At 6 months, mortality was 17.3%, 20.5%, and 46.1%
in those with neither, transient and persistent WRF (P
< .0001 for persistent versus no WRF), strongly suggesting a
worse prognosis for those with persistent declines in kidney
function.
Two studies have recently evaluated the association
of novel biomarkers for predicting AKI/WRF in patients
with AHDF [37, 38]. In a small cohort of 91 ADHF
patients, serum neutrophil gelatinase-associated lipocalin
(NGAL) was measured at the time of admission [37].
In total 35 patients (38%) developed WRF deﬁned as
an increase in SCr ≥ 26.5µmol/L. In patients developing
WRF, serum NGAL was signiﬁcantly higher (194ng/mL
versus 128ng/mL, P = .004). Those with an admission
serum NGAL ≥ 140ng/mL had a 7.4-fold increased risk of
developing WRF. In another small cohort of 125 heart failure
patients, Pﬁster et al. found elevated baseline NT-pro-BNP
predicted subsequent AKI [38].
In both ADHF and ACS, AKI has consistently shown
association with higher morbidity and mortality [11, 20, 45].
In ADHF, AKI is associated with increased risk for both
short- and long-term all-cause and cardiovascular mortality
[10, 11, 15–17, 19, 20, 25, 45]. In addition, data suggest
that there is a biological gradient between AKI severity and
mortality [27]. Several studies have shown development of
AKI in association with ADHF prolonged stay in hospital
[10, 11, 15–17, 19, 20, 25, 45]. Selected studies have also
found that AKI in ADHF was associated with increased
readmission rates [16, 17, 19, 45]. Recently, in a retro-
spective study of 20,063 Medicare beneﬁciaries hospitalized
for ADHF, Kociol et al. found that 17.8% developed AKI
(deﬁned as an increase in SCr ≥ 27µmol/L), with 64.5%
readmitted and 35.4% dying within 1 year [20]. After
adjustment for covariates, AKI was independently associated
with long-term mortality (HR 1.12, 95% CI, 1.04–1.20).
AKI associated with ACS increases the risk of poor
outcome [9, 12–14, 22–24, 28]. Even small acute changesInternational Journal of Nephrology 3
Table 1: Summary of studies fulﬁlling criteria for Acute Cardiorenal Syndrome (CRS Type 1) with a presenting diagnosis of acute
decompensated heart failure.
Study Population Study type
(data source)
AKI (WRF)
deﬁnition
Incidence
AKI (%) Cardiac disease Outcome
Nohria et al.,
2008 [15]
n = 433
Mean Age
56yrs
Male %
DM 34%
HTN 47%
Retrospective
(ESCAPE Trial)
SCr >
26.5µmol/L 29.5 Hospitalized
ADHF
All-cause death (6m) (HR)
increased for SCr > 106.1
AKI (>26.5µmol/L) not
associated with
death/readmission
Logeart et al.,
2008 [16]
n = 416
Age 71yrs
Male 59%
DM 23%
HTN 42%
Prospective SCr >
26.5µmol/L 37
Hospitalized
ADHF Prevalence:
LVEF 0.35
LVEF ≤ 0.45 70%
Prior HF 45%
Prior MI 55%
All-cause death (6m) or
Readmission (adj-HR) 1.74
Increased LOS 3d
Risk persisted whether AKI
transient or not
Metra et al.,
2008 [17]
n = 318
Mean Age
68yrs
Male 60%
DM 34%
HTN 53%
Prospective
SCr >
26.5µmol/L &
≥ 25%
34
Hospitalized
ADHF Prevalence:
Prior MI 51%
Prior HF 58%
CV death or readmission
(adj-HR) 1.47
Increased LOS 7d
Aronson and
Burger [18] n = 467 Prospective SCr >
44.2µmol/L
33.9
Transient 7.9
Persistent
14.3
Hospitalized
ADHF
All-cause death (6m) 17.3%,
20.5%, and 46.1% for no WRF,
transient WRF, persistent WRF
Adj-HR for persistent WRF 3.2
(95% CI, 2,1–5.0)
Belziti et al.,
2010 [19] n = 200 Retrospective
SCr >
26.5µmol/L &
≥ 25%
23 Hospitalized
ADHF
Higher mortality at 1-year (P
< .01)
Rehospitalization for WRF (HR
1.65, P = .003)
Longer median LOS for WRF (9
versus 4 days, P < .05)
Kociol et al.,
2010 [20] n = 20,063 Retrospective SCr >
26.5µmol/L 17.8 Hospitalized
ADHF
1-year mortality 35.4% (HR
1.12, 95% CI, 1.4–1.20)
Rehospitalization 64.5%
SCr: serum creatinine; m: months; d: days; CV: cardiovascular; LOS: length of stay.
in serum creatinine modify the risk of death [14]. Among
those developing AKIs, greater risk of cardiovascular events
such as CHF, recurrent ACS, and stroke and need for
rehospitalization have been shown [14, 23, 24]. Newsome et
al. reported a greater likelihood of progression to ESKD in
those with ACS complicated by AKI [12]. Recently, Goldberg
et al. found increasing severity of and persistent AKI were
associated with higher risk of death in patients surviving ST-
elevation myocardial infarction (STEMI) [21]. This would
imply, similar to studies with ADHF, that there is a biological
gradient between AKI severity and duration and mortality.
These data would suggest that AKI in association with
ADHF or ACS may further exacerbate cardiac injury and/or
function and also contribute to exaggerated declines in
kidneyfunction.Inasmallcohortof141patientswithreper-
fused anterior STEMI, those developing AKI were found
to have higher plasma norepinephrine, BNP, interleukin-
6 levels in the 2 weeks after reperfusion [23]. Moreover,
those developing AKI have higher risk of in-hospital death
(P = .004),majoradversecardiacevents(P = .02),thatcorre-
lated with greater observed left ventricular (LV) remodelling.
This would imply that the observed heart-kidney interface
in Type 1 CRS may synergistically act to further accelerate
injury and/or dysfunction.
3. Type 2 CardiorenalSyndrome:
ChronicCardiorenalSyndrome
This syndrome is characterized by chronic abnormalities in
cardiac function leading to kidney injury or dysfunction.
The term “chronic cardiac abnormalities” encompasses a
number of diﬀerent conditions and may include chronic
LV dysfunction, atrial ﬁbrillation, congenital heart disease,
constrictive pericarditis, and chronic ischemic heart disease
(Table 3).
Observational data clearly show that chronic heart and
kidney disease commonly coexist, but such studies are
unable to determine which of the two disease processes
was primary versus secondary [46]. This therefore presents
challenges when appraising the literature and attempting to
classify patients into the CRS subtype deﬁnitions; it has been4 International Journal of Nephrology
Table 2: Summary of studies fulﬁlling criteria for Acute Cardiorenal Syndrome (CRS Type 1) with a presenting diagnosis of acute coronary
syndrome.
Study Population
(n)
Study type
(data source)
AKI (WRF)
deﬁnition
Incidence
AKI (%) Cardiac disease Outcome
Newsome
et al., 2008
[12]
n = 87,094
Mean Age
77yrs
Male 50%
DM
28%–37%
Retrospective
(CCP) Variable
Any 43.2
SCr
Quartiles:
Q1: 0.1,
13.1;
Q2:0.2, 9.3;
Q3: 0.3–0.5,
12.3;
Q4: 0.6–3.0,
8.4
AMI Prevalence:
Prior MI
31%–35%
Prior HF
21%–35%
All-cause (death (1000 p-y)/HR):
Q1 146/1.1; Q2 157/1.2;
Q3 194/1.3; Q4 275/1.4
ESKD (incidence (1000
p-y)/HR):
Q1 2.3/1.5; Q2 3.6/2.0;
Q3 6.3/2.4; Q4 20/3.3
Parikh et al.,
2008 [13]
n = 147,007
Age 76–78yrs
Male
49%-50%
DM
29%–41%
Retrospective
(CCP)
SCr
(µmol/L):
Mild
(26.5–35.4);
Mod
(44.2–88.4);
Severe (≥88.4)
Any 19.4,
Mild 7.1,
Mod 7.1,
Severe 5.2
AMI Prevalence:
Prior AMI
30%–36%
Prior HF
19%–35%
All-cause (10yr) (death
(crude%)/adj-HR):
None 68/1.00; Mild 79/1.15; Mod
88/1.23 Severe >90/1.33
Goldberg et al.,
2009 [21]
n = 1957
Age 59–70yrs
Male 79.4%
DM 26.2%
Retrospective
SCr
(µmol/L):
Mild
(26.5–44.2),
Mod-Severe
(>44.2)
Mild 8.0
Mod-Severe
7.1
Prior AMI 20.9%
Adj-HR mortality: Mild
transient 1.2; Mild persistent 1.8;
Mod-severe transient 1.7;
Mod-severe persistent 2.4
Mielniczuk
et al., 2009
[22]
n = 3795 Retrospective SCr > 25%
over 1-month 5—
Adj-HR 1.6 (95% CI, 1.1–2.3) for
composite CV death, recurrent
ACS, HF or stroke
Anzai et al.,
2010 [23]
n = 141
Age 63yrs
Male 87%
DM 36%
Prospective
SCr >
26.5µmol/L
within 48hrs
22 Anterior STEMI
Higher in-hospital death (P
= .004) and major adverse
cardiac events (P = .02)
Marenzi et al.,
2010 [24]
n = 97
Age 63–69yrs
Male 69%
DM 18.6%
Prospective SCr > 25% 55 STEMI + IABP
In-hospital death (RR 12.3, 95%
CI, 1.8–84.9, P < .001). AKI
associated with age > 75yrs,
LVEF < 40%, mechanical
ventilation.
WRF: worsening renal function; SCr: serum creatinine; wks: weeks; m: months; CKD: chronic kidney disease; ESKD: end-stage kidney disease.
suggested to use the term Type 2/4 in these situations [8].
Large database studies often describe patient populations
based on the existence of one disease process (i.e., HF) and
subsequently estimate the occurrence of the other (CKD).
In the ADHERE study, a large dataset of 118,465
individual hospitalizations for ADHF, 27.4%, 43.5%, and
13.1% of patients were found to have mild, moderate, and
severekidneydysfunctionathospitaladmission[39].Greater
severity of kidney dysfunction correlated with worse clinical
outcomes, including need for ICU admission, need for
mechanical ventilation, longer hospitalization, and higher
mortality. In the Digitalis Investigation Group trial, preexist-
ing CKD was found in 45% of chronic HF patients and was
associated with higher rate of hospitalization and death [39].
There was also evidence of a biologic gradient between CKD
severity and outcome.
The Atherosclerosis Risk in Communities (ARIC) and
CardiovascularHealth(CHS)studiesrecentlyprovidedsome
additional insight on the epidemiology of Type 2 CRS
[40]. Patients with baseline CVD comprised 12.9% of the
study cohort. At study entry, these patients had a mean
SCr 79.6µmol/L and estimated GFR 86.2ml/min/1.73m2.
A f t e ra na v e r a g ef o l l o w - u po f9 . 3y e a r s ,7 . 2 %o fC V D
patients had declines in kidney function when deﬁned as
an increase in SCr ≥ 35.4µmol/L and 34% when deﬁned as
a decline in eGFR ≥ 15ml/min/1.73m2. During follow-up,
5.6%developednewCKD.Bymultivariableanalysis,baseline
CVD was independently associated with both decline in
kidney function and development of new CKD. These
data strongly suggest that CVD is an important risk for
measurable declines in kidney function (OR 1.70, 95% CI
1.36–2.31) and CKD (OR 1.75, 95% CI 1.32–2.32) and
empirical proof of the concept of Type 2 CRS.
One clear example of CRS Type 2 is congenital heart
disease, in which the heart disease temporally precedes any
kidney disease. “Cyanotic nephropathy” (CN) has long beenInternational Journal of Nephrology 5
Table 3: Summary of studies fulﬁlling criteria for Chronic Cardiorenal Syndrome (CRS Type 2).
Study Population
(n)
Study type
(data source) Cardiac disease CKD Cardiac-speciﬁc
outcomes Outcomes (%)
Heywood
et al., 2007
[39]
N = 118,465
Mean Age
61.7–76.3yrs
Male
42%–57%
ADHERE
registry ADHF
eGFR 60–89: 27.4%;
eGFR 30–59: 43.5%;
eGFR 15–29: 13.1%;
eGFR < 15: 7%
Use of
cardioprotective
meds (ACE-I and
ARB) decreased
with increasing
degree of CKD
OR for in-hospital
mortality: eGFR ≥ 90: 1.0;
eGFR 60–89: 2.3; eGFR
30–59: 3.9; eGFR 15–29:
7.6; eGFR < 15: 6.5
Elsayed et al.,
2007 [40]
N = 13826
Mean Age
58yrs
Male 56%
Prospective
(ARIC and
CHS)
Baseline CVD
in 12.9%
eGFR decrease of at
least 15ml/min/1.73
m2 to a ﬁnal level < 60
ml/min/1.73 m2 was
seen in 34% of patients
with baseline CVD
NA
OR for development of
kidney disease 1.54 (CVD
versus non-CVD)
Ahmed et al.,
2007 [41]
N total =
7788
Mean Age
59.9–65.4yrs
Male
76%–81%
Retrospective
(DIG trial);
Propensity-
matched
study
Ambulatory
patients with
CHF
eGFR < 60 in 45%
Ag r a d e d
association was
found between
CKD-related
deaths and LVEF
Matched HR: (CKD versus
non-CKD) All-cause death
1.71
Campbell
et al., 2009
[42]
N total =
7788
Mean Age
59.9–65.4yrs
Male
76%–81%
Retrospective
(DIG trial);
Propensity-
matched
study
Ambulatory
patients with
CHF
eGFR < 60 in 45%
Matched HR:
(CKD versus
non-CKD) CV
hospitalization
1.17 HF
hospitalization
1.08 CV death
1.24 HF death
1.42
Matched HR: (CKD versus
non-CKD) All-cause
hospitalization 1.18
Dimopoulos
et al., 2008
[43]
N = 1102
Mean Age
36yrs
Male 48.5%
Retrospective
(single center)
Adult
congenital
heart disease
eGFR 60%–89 41%
eGFR < 60 9% NA All-cause death (HR) eGFR
≥ 90 1.0; eGFR < 60 3.25
Hillege et al.,
2003 [44]
N = 298
Mean Age
51–67yrs
Male 70%
DM
16%–27%
HTN
6%–14%
Retrospective
(CATS trial)
1st anterior
wall MI
Change in GFRc
Placebo:
−5.5ml/min/yr
Captopril:
−0.5ml/min/yr
New CHF (RR)
GFRc > 103: 1.0
GFRc 81–103:
1.23 GFRc < 81:
1.55
All-Cause death: 1-yr 8%
ARIC: atherosclerosis risk in communities study; ADHF: acute decompensated heart failure: GFRc: GFR estimated by Cockroft Gault; CATS: captopril and
thrombolysis study; CVD: cardiovascular disease; CVS: cardiovascular health study; DIG: digoxin investigator group.
recognizedasapotentialcomplicationofcyanoticcongenital
heart disease [47, 48]. Infants born with congenital heart
defect, in the majority of circumstances, have normal
kidneys. Dimopoulos et al. studied 1102 patients (mean
age 36yrs) surviving into adulthood with congenital heart
disease [43]. Amongst this cohort, >50% had evidence of
kidney dysfunction that was considered mild (eGFR 60 to
89ml/min per 1.73m2) in 41% and moderate-severe (eGFR
< 60ml/min per 1.73m2) in 9%. Patients with Eisenmenger
physiology had the lowest eGFR and the highest prevalence
of moderate or severe reduced GFR (18%). Similarly, there
was a trend towards greater kidney dysfunction in patients
with more complex anatomy. However, kidney dysfunction
was detected even among patients characterized as having
“simple” defects. Importantly, kidney dysfunction had a
substantial impact on mortality (propensity score-weighted
HR 3.25, P = .002 for impaired versus normal GFR).
4. Acute Reno-CardiacSyndrome (Type 3 CRS)
The Acute Reno-Cardiac Syndrome (Type 3 CRS) is char-
acterized by acute worsening of kidney function that leads
to acute cardiac injury and/or dysfunction, such as acute
myocardial infarction, congestive heart failure, or arrhyth-
mia. Conditions that may contribute to this syndrome
include cardiac surgery-associated AKI, AKI after major
noncardiac surgery, contrast-induced AKI (CI-AKI), other
drug-induced nephropathies, and rhabdomyolysis.6 International Journal of Nephrology
The association of AKI and acute cardiac dysfunc-
tion with these conditions likely shares similar predispos-
ing pathophysiologic mechanisms and risk factors for
development (i.e., volume overload, systemic hypertension,
retention of uremic solutes, hyperkalemia). However, the
pathophysiologic mechanisms contributing to Type 3 CRS
are likely to extend beyond simply retention of uremic
solutes and/or volume overload. Deﬁning the epidemiology
of Type 3 CRS is challenging for several reasons. First, there
is considerable heterogeneity in predisposing conditions
causing AKI. Second, AKI has been variably deﬁned across
studies. Third, there is likely variable baseline risk for acute
cardiac dysfunction across populations, such as increased
susceptibility in selected individuals with subclinical cardio-
vascular disease. Finally, few clinical studies focused on AKI
havereportedontheeventratesofacutecardiacdysfunction.
Therefore, estimates of incidence and associated outcomes
of acute cardiac dysfunction associated with AKI are largely
context- and disease-speciﬁc.
For example, contrast media administration is a leading
cause of iatrogenic AKI following diagnostic and inter-
ventional procedures and is associated with major adverse
eﬀects, progression of CKD, and consumption of health
resources [49]. While AKI is most often attributable to the
administration of contrast media, additional confounding
factors, such as atheroembolic disease, renal hypoperfusion,
concomitant nephrotoxins, may also be contributory. The
reported incidence is highly variable depending on the
population-at-risk being evaluated (i.e., age, CKD, DM,
HF) and the type of procedure performed (i.e., emergent,
intravascular,type,andvolumeofcontrastmedia).Incidence
estimates have been reported in the range of 1%–40% [49–
51]. The natural history of CI-AKI in many patients may
follow an asymptomatic rise in serum creatinine with early
return to baseline, and these patients would not be expected
to fulﬁll the criteria for Acute Reno-Cardiac Syndrome
(Type 3 CRS). However, in an estimated 0.2%–1.1%, AKI
progresses to require the initiation of renal replacement
therapy (RRT) [49, 50, 52]. In these patients, AKI may be
associatedwithvolumeoverload,retentionofuremicsolutes,
pulmonary edema, and cardiac arrhythmias. Importantly,
those at-risk for developing CI-AKI requiring RRT may be
identiﬁable ap r i o r i .H o w e v e r ,t h ed i ﬃculty in evaluating
the epidemiology of Acute Reno-Cardiac Syndrome (Type 3
CRS) attributable to CI-AKI is that few studies have specif-
ically reported the temporal occurrence of cardiovascular
events following contrast media exposure
[53].
5. ChronicReno-CardiacSyndrome
(Type4CRS)
The Chronic Reno-Cardiac Syndrome (Type 4 CRS) is a
condition where primary CKD contributes a reduction in
cardiacfunction,suchascardiacremodelling,leftventricular
diastolic dysfunction or hypertrophy, and/or an increased
risk for cardiovascular events, such as myocardial infarction,
heart failure, or stroke. This CRS subtype refers to cardiac
dysfunction and/or disease primarily occurring in response
to CKD (Table 4).
Observational data have evaluated the cardiovascular
event rates and outcomes in selected CKD-speciﬁc popu-
lations [54, 56, 57, 59–63]. Most have been retrospective
and/or secondary post hoc analyses from large clinical
registries or randomized trials. As mentioned above, this
type of data cannot establish whether the primary process
is the kidney disease (CRS Type 4) or the heart disease
(CRS Type 2). Furthermore, deﬁning the epidemiology of
Type 4 CRS is challenging, and estimates are variable due
to diﬀerences in (1) the populations-at-risk, (2) the clinical
outcomes evaluated, (3) duration of time for ascertainment
of study endpoints, and (4) the operational deﬁnitions used
for deﬁning CKD, cardiac disease, and/or mortality (i.e., all-
cause or CVD-speciﬁc).
For example, the populations-at-risk in these studies,
b a s e do nt h ep r e s e n c ea n ds e v e r i t yo fC K D ,r a n g e df r o m
near normal kidney function to ESKD. In a secondary
analysis of the Hemodialysis (HEMO) Study, Cheung et
al. found that 80% of ESKD patients had cardiac dis-
ease at enrollment [60]. Older patients, diabetics, and
those having received a longer duration of maintenance
hemodialysis (>3.7 years) had higher prevalence of pre-
existing cardiac disease. During follow-up, 39.8% were
admitted to hospital for cardiac-related diagnoses. Of these,
42.7% were attributable to ischemic CHD. Of the 39.4%
of cardiac deaths, 61.5% were attributable to ischemic
CHD. Baseline cardiac disease was signiﬁcantly predictive
of cardiac-speciﬁc death during follow-up (Relative Risk
2.57). Moreover, recent data have suggested that chronic
maintenance hemodialysis induces repetitive myocardial
injuryandcanacceleratedeclinesinmyocardialperformance
[64].
In CKD patients not receiving maintenance RRT, the
prevalence of CVD varies considerably with CKD severity
and the overall time-at-risk (i.e., duration of time with
diagnosis of CKD) [58, 59, 62]. The risk of CVD events and
death is also likely further modiﬁed by older age, comorbid
illness, and presence of concomitant HF [54, 59, 62, 65].
In data from the NHANES II study, Muntner et al. found
CVD prevalence of 4.5%, 7.9%, and 12.9% for patients
with eGFR ≥ 90, 70–89, and < 70mL/min/cm2,r e s p e c t i v e l y
[55]. Likewise, in a large population-based cohort, Go et
al. found similar graded increases in CVD prevalence and
HF, along with higher risk of subsequent cardiac events
duringfollow-upassociatedwithdegreeofdeclineineGFR<
60mL/min/1.73cm2 [56]. This dose-response gradient in
CVD prevalence by severity of CKD was also associated with
higher trends in cardiac-speciﬁc and all-cause mortality [55–
58]. Observational data have also shown that CKD acceler-
ates the risk for and development of CVD [3, 59, 62]. This
accelerated risk for cardiovascular events and disease in CKD
may be the consequence of the unique pathophysiology that
exists in these patients including hyper-homocysteinemia,
elevated lipoprotein (a), oxidative stress, endothelial dys-
function, chronic inﬂammation (i.e., elevated C-reactive
protein, interleukin-6), vascular remodelling (i.e., increased
myocardial arteriolar wall thickness, reduced myocardialInternational Journal of Nephrology 7
Table 4: Summary of selected studies fulﬁlling criteria for Chronic Reno-Cardiac Syndrome (Type 4).
Study Population (n) Study type
(data source) CKD stage Cardiac outcomes
(%) Outcomes (%)
Herzog et al., 1998
[54]
n = 34,189
Age ≥ 65yrs 55%
Male 56%
Retrospective
(USRDS) ESKD
Cardiac-Death: 1-yr
41%; 2-yr 52%; 5-yr
70.2%; 10-yr 83%
All-cause: 1-yr 59%; 2-yr 73%;
5-yr 90%; 10-yr 97%
Muntner et al.,
2002 [55]
n = 6,534
Age 48–63yrs
Male 51%–61%
Retrospective
(NHANES II)
eGFR < 70
75.9%
CV-Death (rate per
1000 p-y): eGFR ≥
90: 4.1; eGFR 70–89:
8.6; eGFR < 70: 20.5
All-cause death (HR): eGFR ≥
90: 1.00 eGFR 70–89: 1.64; eGFR
< 70: 2.00
Go et al., 2004 [56]
n = 1.1 million
Mean Age 52yrs
Male 45%
Retrospective
(Kaiser
Permanente)
≥ CKD stage III
or eGFR < 60
CV Event (rate per
100 p-y/HR): eGFR
45–59: 3.65/1.4; eGFR
30–44: 11.3/2.0; eGFR
15–29: 21.8/2.8; eGFR
< 15: 36.6/3.4
All-cause mortality (per 100
p-y/HR): eGFR 45–59: 1.1/1.2;
eGFR 30–44: 4.8/1.8; eGFR
15–29: 11.4/3.2; eGFR < 15:
14.1/5.9
Foley et al., 2005
[3]
n = 1,091,201
Age ≥ 75yrs 56.1
Male 39%
Retrospective
(Medicare/USRDS)
CKD 3.8%
(diagnostic
coding)
CV Event Incidence:
AMI 4–7 per 100 p-y;
CHF 31–52 per 100
p-y; (HR 1.28–1.79)
All-cause death: HR 1.38–1.56
HIllege et al., 2006
[57]
n = 2,680
Mean Age 65yrs
Male 67%
Retrospective
(CHARM) eGFR < 60 36%
CV Death/Hosp.
(HR) eGFR ≥ 90: 1.0;
eGFR 75–89: 1.17;
eGFR 60–74: 1.24;
eGFR 45–59: 1.54
eGFR < 45: 1.86
All-cause death (HR) eGFR ≥ 90:
1.0; eGFR 75–89: 1.13; eGFR
60–74: 1.14; eGFR 45–59: 1.50
eGFR < 45: 1.91
McCullough et al.,
2007 [58]
n = 37,153
Mean Age 53yrs
Male 31%
Retrospective
(KEEP)
eGFR< 60
14.8%
Prevalence CVD
(OR): eGFR ≥ 90 1.0;
eGFR 60–89 1.1;
eGFR 30–59 1.4;
eGFR < 30 1.3
All-cause death (HR): CKD only
1.98; CVD only 3.02 CKD +
CVD 3.80
McCullough et al.,
2008 [59]
n = 31,417
Mean Age 45yrs
Male 24.5%
Retrospective
(KEEP)
eGFR< 60 or
ACR ≥ 30:
20.6%
Risk CVD/death
(OR): CKD 1.44 No
CKD 1.0
Worst survival for combined
CKD and CVD at time of
screening
ESKD: end-stage kidney disease; CKD: chronic kidney disease; DM: diabetes mellitus; HTN: hypertension; CHF: congestive heart failure; CVD:
cerebrovascular disease; MA: microalbuminuria: CHD: coronary heart disease; LVH: left ventricular hypertrophy; CV: cardiovascular; eGFR: estimated
glomerular ﬁltration rate; ADHF: acute decompensated heart failure.
capillary density, increased cardiac interstitium [66]), alter-
ations in platelet aggregation, neurohormonal activation,
volume overload, reduced parenchymal mass, and deﬁciency
in various hormones (i.e., vitamin D, erythropoietin) [67].
Another important consideration is that patients with CKD
have often been excluded from clinical trials of interventions
in CVD [4] and may receive less or suboptimal risk mod-
ifying and/or cardioprotective therapies, and perhaps as a
consequence, receive less or suboptimal risk modifying and
cardioprotective therapies such as aspirin, beta-blockers,
and angiotensin-converting inhibitors despite evidence to
suggest that CKD patients may similarly beneﬁt [46, 68–70].
Finally, the genuine concern for treatment toxicities, intoler-
ance, and/or risks in CKD patients or AKI may be such that
therapy is not oﬀered due to an unfounded perception of a
less favourable risk-beneﬁt ratio. These factors, in part, may
provide explanation for the excess of CVD and associated
poor outcomes for CKD patients.
Analogous to congenital heart disease being a prototype
condition for CRS Type 2, genetic renal diseases can also be
a similar example for CRS Type 4, in that the renal disease
temporally precedes the cardiac disease. Autosomal domi-
nant polycystic kidney disease (ADPKD) is one of the most
common genetic renal diseases worldwide and is the fourth
leading cause of ESRD in the United States of America
[71]. Cardiovascular complications are the leading cause of
death in ADPKD, and multiple cardiac conditions have been
described in these patients. As with CKD in general, the
prevalence of left ventricular hypertrophy (LVH) is higher
in ADPKD compared to a control population, and the
frequencyincreasesprogressivelyasGFRdecreases.However,
several studies have also shown increased LV mass indices,
LV diastolic dysfunction, and endothelial dysfunction in
young otherwise normotensive ADPKD subjects with well-
preserved renal function [72].
6. Secondary CardiorenalSyndromes
(Type5CRS)
The Type 5 CRS is characterized by an acute or chronic
systemic illness that concurrently induces cardiac and kidney8 International Journal of Nephrology
Table 5: Summary of potential etiologies for acute and chronic
Secondary Cardiorenal Syndromes (Type 5).
(a) Acute Systemic Illness
Severe sepsis/septic shock
Speciﬁc infections
HIV
Malaria
Leptospirosis
Hepatitis C virus
Drug toxicity
Cocaine
Heroine
Calcium-channel blockers
Cancer chemotherapy
Connective tissue diseases
Systemic lupus erythematosus
Scleroderma
Antiphospholipid antibody syndrome
Microangiopathy
TTP/HUS
Pregnancy
Malignant hypertension
Hemorrhagic shock
Vasculitis
Malignancy (i.e., lymphoma/leukemia)
(b) Chronic Systemic Illness
Hypertension
Diabetes Mellitus
Primary/Secondary Amyloidosis
Multiple Myeloma/Paraproteinemias
Sarcoidosis
Liver Cirrhosis
Primary/Secondary Pulmonary Hypertension
injury and/or dysfunction. Limited data is available on
the epidemiology of Secondary Cardiorenal Syndromes
due largely to vast number of contributing acute and/or
chronic systemic conditions that may predispose to it.
Accordingly, estimates of incidence, risk identiﬁcation, and
outcomes for Type 5 CRS are considered largely disease,
and/or context-speciﬁc and may be time-varying. Impor-
tantly, there is currently an incomplete understanding of
the pathophysiologic mechanisms of secondary cardiac-
kidney interaction. Speciﬁcally, whether concomitant car-
diac and kidney dysfunction in systemic illness is merely
coexisting or whether there is genuine bidirectional inter-
action that may directly contribute to aggravated dys-
function in either organ system remains unclear (see
Table 5).
Sepsis represents a prototypical condition that may cause
an acute form of Type 5 CRS. Approximately 11%–64%
of septic patients develop AKI [73], and 46%–58% have
sepsis as a major contributing factor to development of
AKI [74]. Observational data have shown higher morbidity
and mortality for those with septic AKI when compared
to either sepsis or AKI alone [74, 75]. Similarly, abnor-
malities in cardiac function are common in septic patients
[76]. The incidence of cardiac dysfunction in sepsis is
conditional on the population-at-risk being studied, the
deﬁnition used for detection of cardiac dysfunction (i.e.,
troponin, B-type natriuretic peptide, pulmonary artery
catheter, echocardiography), severity of illness, resuscita-
tion, and duration of illness prior to evaluation. However,
observational data have found that approximately 30%–
80% have elevated cardiac-speciﬁc troponins that often
correlate with reduced cardiac function [77]. Accordingly,
coexisting acute kidney and myocardial dysfunction is
common in sepsis; however, there is a lack of integrative
and epidemiologic studies that have speciﬁcally evaluated
the pathophysiology, incidence, risk identiﬁcation, and asso-
ciated outcomes for septic patients with concomitant AKI
and myocardial depression who fulﬁll criteria for Type 5
CRS.
7. Conclusions
Considerable data from observational studies and clinical
trials have accumulated to show that acute or chronic
cardiac disease can directly contribute to acute or chronic
worsening kidney function and vice versa. The Cardiorenal
Syndrome subtypes are characterized by important heart-
kidney interactions that share some similarities in patho-
physiology, however, appear to have important discrimi-
nating features, in terms of predisposing or precipitating
events, risk identiﬁcation, natural history, and outcomes.
The Type 1 CRS is common, with incidence estimates
of AKI in ADHF or ACS between 24%–45% and 9%–
19%, respectively. Type 1 CRS clearly translates into higher
morbidity and worse clinical outcome. Chronic heart disease
and CKD are increasingly prevalent and frequently coexist.
Accordingly, this presents challenges for applying the pro-
posed deﬁnitions for Type 2 and 4 CRS “retrospectively” to
the existing literature when the primary versus secondary
process cannot be clearly distinguished. The rate of pro-
gression of preexisting CKD in patients with established
cardiovascular disease deserves further study, as well as the
eﬀect of cardioprotective therapies on these renal endpoints.
Prospective research incorporating novel biomarkers of
kidney-heart interaction is needed for better understanding
of both Types 2 and 4 CRS, along with studies of CKD-
speciﬁc interventions in Type 4 CRS. Due to heterogeneity,
the incidence and outcome estimates associated Type 3
CRS are largely context- and disease-speciﬁc. Limited data
is available on the pathophysiology or epidemiology of
secondary Type 5 CRS. Accordingly, the epidemiology of
Type 5 CRS is also largely disease- and context-speciﬁc. In
summary, there is a clear need for additional prospective
studies to characterize the epidemiology of heart-kidney
interactions across the CRS subtypes, not only for a better
understanding of the overall burden of disease, but also
for risk identiﬁcation and design of potential targets for
intervention.International Journal of Nephrology 9
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